Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

doi:10.1007/s11684-021-0847-4

. 2021 Aug;15(4):644-648.

doi: 10.1007/s11684-021-0847-4. Epub 2021 Apr 28.

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai^#¹, Tianhui Zhou^#¹, Xiaogang Xiang¹, Jie Lu¹, Haiguang Xin², Qing Xie³

Affiliations

¹ Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
² Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. allanxin@hotmail.com.
³ Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xieqingrjh@163.com.

^# Contributed equally.

PMID: 33909259
PMCID: PMC8079842
DOI: 10.1007/s11684-021-0847-4

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai et al. Front Med. 2021 Aug.

. 2021 Aug;15(4):644-648.

doi: 10.1007/s11684-021-0847-4. Epub 2021 Apr 28.

Authors

Rongtao Lai^#¹, Tianhui Zhou^#¹, Xiaogang Xiang¹, Jie Lu¹, Haiguang Xin², Qing Xie³

Affiliations

¹ Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
² Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. allanxin@hotmail.com.
³ Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xieqingrjh@163.com.

^# Contributed equally.

PMID: 33909259
PMCID: PMC8079842
DOI: 10.1007/s11684-021-0847-4

Abstract

The coronavirus disease 2019 (COVID-19) has caused global public health and economic crises. Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic. The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the attractive treatment strategies for COVID-19. Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells. A single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibility of targeted epitope mutation, leading to viral escape. In addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection. These risks can be reduced using multiple mAbs that target nonoverlapping epitopes. Thus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.

Keywords: COVID-19; SARS-CoV-2; antibody cocktail; neutralizing antibody; therapeutic strategy.

PubMed Disclaimer

Cited by

Antibody-dependent enhancement of coronaviruses.
Tao T, Tian L, Ke J, Zhang C, Li M, Xu X, Fan J, Tong Y, Fan H. Tao T, et al. Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025. Int J Biol Sci. 2025. PMID: 39990674 Free PMC article. Review.

References

1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH, WHO Strategic and Technical Advisory Group for Infectious Hazards COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–1018. doi: 10.1016/S0140-6736(20)30673-5. - DOI - PMC - PubMed
1. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, Khan IA, Anis K, Karim AH. Treatment options for COVID-19: a review. Front Med (Lausanne) 2020;7:480. doi: 10.3389/fmed.2020.00480. - DOI - PMC - PubMed
1. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849. - DOI - PMC - PubMed
1. Mulangu S, Dodd LE, Davey RT, Jr., Tshiani M, Proschan M, Mukadi D, Lusakibanza M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group. Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Valllée D, Nordwall J, PALM Consortium Study Team A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303. doi: 10.1056/NEJMoa1910993. - DOI - PMC - PubMed
1. Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther. 2020;3(2):109–114. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH, WHO Strategic and Technical Advisory Group for Infectious Hazards COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–1018. doi: 10.1016/S0140-6736(20)30673-5. - DOI - PMC - PubMed

[2] Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH, WHO Strategic and Technical Advisory Group for Infectious Hazards COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–1018. doi: 10.1016/S0140-6736(20)30673-5. - DOI - PMC - PubMed

[3] Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, Khan IA, Anis K, Karim AH. Treatment options for COVID-19: a review. Front Med (Lausanne) 2020;7:480. doi: 10.3389/fmed.2020.00480. - DOI - PMC - PubMed

[4] Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, Khan IA, Anis K, Karim AH. Treatment options for COVID-19: a review. Front Med (Lausanne) 2020;7:480. doi: 10.3389/fmed.2020.00480. - DOI - PMC - PubMed

[5] Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849. - DOI - PMC - PubMed

[6] Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849. - DOI - PMC - PubMed

[7] Mulangu S, Dodd LE, Davey RT, Jr., Tshiani M, Proschan M, Mukadi D, Lusakibanza M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group. Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Valllée D, Nordwall J, PALM Consortium Study Team A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303. doi: 10.1056/NEJMoa1910993. - DOI - PMC - PubMed

[8] Mulangu S, Dodd LE, Davey RT, Jr., Tshiani M, Proschan M, Mukadi D, Lusakibanza M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group. Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Valllée D, Nordwall J, PALM Consortium Study Team A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303. doi: 10.1056/NEJMoa1910993. - DOI - PMC - PubMed

[9] Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther. 2020;3(2):109–114. - PMC - PubMed

[10] Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther. 2020;3(2):109–114. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Affiliations

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous